{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:20:37Z","timestamp":1789572037783,"version":"build-2803163510"},"reference-count":111,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"14","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,5,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the<\/jats:italic>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.asco.org\/guideline-methodology\">\n                        <jats:italic toggle=\"yes\">ASCO Guidelines Methodology Manual<\/jats:italic>\n                      <\/jats:ext-link>\n                      <jats:italic toggle=\"yes\">. ASCO Guidelines follow the<\/jats:italic>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.asco.org\/rwc\">\n                        <jats:italic toggle=\"yes\">ASCO Conflict of Interest Policy for Clinical Practice Guidelines<\/jats:italic>\n                      <\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">\n                        Clinical Practice Guidelines and other guidance (\u201cGuidance\u201d) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in\n                        <jats:xref ref-type=\"app\">Appendix 1<\/jats:xref>\n                        and\n                        <jats:xref ref-type=\"app\">Appendix 2<\/jats:xref>\n                        (online only) for more\n                      <\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>To provide evidence-based recommendations on the use of systemic therapy in different types of thyroid cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>The American Society of Clinical Oncology convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. The literature search included studies published between January 1, 2000, and November 5, 2025, and comprised systematic reviews, meta-analyses, randomized controlled trials, and observational studies. Outcomes of interest included overall survival, disease-free survival, and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>A total of 66 publications were identified to inform the evidence base for this guideline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RECOMMENDATIONS<\/jats:title>\n                    <jats:p>Evidence-based recommendations address the use of systemic therapy in patients with well-differentiated, differentiated high-grade or poorly differentiated, anaplastic, and medullary thyroid cancer.<\/jats:p>\n                    <jats:p>\n                      Additional information is available at\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/ascopubs.org\/topics\/asco-guidelines\/head-neck-cancer\">https:\/\/ascopubs.org\/topics\/asco-guidelines\/head-neck-cancer<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-26-00235","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T19:59:07Z","timestamp":1775073547000},"page":"1349-1372","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":5,"title":["Systemic Treatment of Thyroid Cancer: ASCO Guideline"],"prefix":"10.1200","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4972-1477","authenticated-orcid":false,"given":"Nabil F.","family":"Saba","sequence":"first","affiliation":[{"name":"Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2074-1896","authenticated-orcid":false,"given":"Nofisat","family":"Ismaila","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology (ASCO), Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3207-8227","authenticated-orcid":false,"given":"Douglas","family":"Adkins","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant","family":"Agrawal","sequence":"additional","affiliation":[{"name":"University of Chicago Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-0218","authenticated-orcid":false,"given":"Neil","family":"Akhave","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S.","family":"Blomain","sequence":"additional","affiliation":[{"name":"Thomas Jefferson, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5124-1811","authenticated-orcid":false,"given":"Maria E.","family":"Cabanillas","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Chen","sequence":"additional","affiliation":[{"name":"City of Hope Cancer Center, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Galloway","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4012-3251","authenticated-orcid":false,"given":"Guilherme","family":"Harada","sequence":"additional","affiliation":[{"name":"Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2861-3899","authenticated-orcid":false,"given":"Dapeng","family":"Li","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salem I.","family":"Noureldine","sequence":"additional","affiliation":[{"name":"George Washington University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Scharpf","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5015-2964","authenticated-orcid":false,"given":"Lova L.","family":"Sun","sequence":"additional","affiliation":[{"name":"Penn Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Tang","sequence":"additional","affiliation":[{"name":"GBMC Health Care, Towson, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2629-2289","authenticated-orcid":false,"given":"Lori","family":"Wirth","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Worden","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1002-8301","authenticated-orcid":false,"given":"Dan P.","family":"Zandberg","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5497-2831","authenticated-orcid":false,"given":"Beth M.","family":"Beadle","sequence":"additional","affiliation":[{"name":"Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00020-X"},{"key":"e_1_3_9_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.11.012"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.4019"},{"key":"e_1_3_9_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5380-3"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae617"},{"key":"e_1_3_9_9_2","first-page":"1184","article-title":"Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: Results of a randomized, phase 2, open-label multicenter trial","volume":"32","author":"Busaidy NL","year":"2022","unstructured":"Busaidy NL, Konda B, Wei L, et al: Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: Results of a randomized, phase 2, open-label multicenter trial. Thyroid 32:1184-1192, 2022","journal-title":"Thyroid"},{"key":"e_1_3_9_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0046"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30166-8"},{"key":"e_1_3_9_12_2","first-page":"467","article-title":"A phase 2 study of encorafenib in combination with binimetinib in patients with metastatic BRAF-mutated thyroid cancer in Japan","volume":"34","author":"Tahara M","year":"2024","unstructured":"Tahara M, Kiyota N, Imai H, et al: A phase 2 study of encorafenib in combination with binimetinib in patients with metastatic BRAF-mutated thyroid cancer in Japan. Thyroid 34:467-476, 2024","journal-title":"Thyroid"},{"key":"e_1_3_9_13_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae454"},{"key":"e_1_3_9_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037655"},{"key":"e_1_3_9_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.15027"},{"key":"e_1_3_9_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2022.2102000"},{"key":"e_1_3_9_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14479"},{"key":"e_1_3_9_18_2","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ20-0171"},{"key":"e_1_3_9_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-02167-6"},{"key":"e_1_3_9_20_2","doi-asserted-by":"publisher","DOI":"10.1055\/a-1023-4214"},{"key":"e_1_3_9_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1368466"},{"key":"e_1_3_9_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309719"},{"key":"e_1_3_9_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30252"},{"key":"e_1_3_9_24_2","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-23-0134"},{"key":"e_1_3_9_25_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0363"},{"key":"e_1_3_9_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00120-0"},{"key":"e_1_3_9_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005651"},{"key":"e_1_3_9_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02503"},{"key":"e_1_3_9_29_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2024.0495"},{"key":"e_1_3_9_30_2","doi-asserted-by":"publisher","unstructured":"Hadoux J Al Ghuzlan A Lamartina L et al: Patterns of treatment failure after selective rearranged during transfection (RET) inhibitors in patients with metastatic medullary thyroid carcinoma. JCO Precis Oncol 10.1200\/PO.23.00053","DOI":"10.1200\/PO.23.00053"},{"key":"e_1_3_9_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.25832"},{"key":"e_1_3_9_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx479"},{"key":"e_1_3_9_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4659"},{"key":"e_1_3_9_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2950"},{"key":"e_1_3_9_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.5040"},{"key":"e_1_3_9_36_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0557"},{"key":"e_1_3_9_37_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1127"},{"key":"e_1_3_9_38_2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0129"},{"key":"e_1_3_9_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.01.029"},{"key":"e_1_3_9_40_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP161259.OR"},{"key":"e_1_3_9_41_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3713"},{"key":"e_1_3_9_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.6604"},{"key":"e_1_3_9_43_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0206"},{"key":"e_1_3_9_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01491-3"},{"key":"e_1_3_9_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60421-9"},{"key":"e_1_3_9_46_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406470"},{"key":"e_1_3_9_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70335-2"},{"key":"e_1_3_9_48_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2013.0078"},{"key":"e_1_3_9_49_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0285"},{"key":"e_1_3_9_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.27940"},{"key":"e_1_3_9_51_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0073"},{"key":"e_1_3_9_52_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.4729"},{"key":"e_1_3_9_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.6785"},{"key":"e_1_3_9_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.014"},{"key":"e_1_3_9_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02321-8"},{"key":"e_1_3_9_56_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02727"},{"key":"e_1_3_9_57_2","first-page":"5342","article-title":"The impact of BRAF targeting agents in advanced anaplastic thyroid cancer: A multi-institutional retrospective study in Taiwan","volume":"12","author":"Chang CF","year":"2022","unstructured":"Chang CF, Yang MH, Lee JH, et al: The impact of BRAF targeting agents in advanced anaplastic thyroid cancer: A multi-institutional retrospective study in Taiwan. Am J Cancer Res 12:5342-5350, 2022","journal-title":"Am J Cancer Res"},{"key":"e_1_3_9_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2022.10.017"},{"key":"e_1_3_9_59_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0504"},{"key":"e_1_3_9_60_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0573"},{"key":"e_1_3_9_61_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.920857"},{"key":"e_1_3_9_62_2","unstructured":"Cabanillas ME Busaidy NL Zafereo M et al: Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center phase 2 clinical trial. medRxiv. 10.1101\/2025.11.09.25339786"},{"key":"e_1_3_9_63_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03093"},{"key":"e_1_3_9_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.06.044"},{"key":"e_1_3_9_65_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2012.0103"},{"key":"e_1_3_9_66_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1520"},{"key":"e_1_3_9_67_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00025"},{"key":"e_1_3_9_68_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02425-y"},{"key":"e_1_3_9_69_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00599"},{"key":"e_1_3_9_70_2","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-11-0351"},{"key":"e_1_3_9_71_2","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2023.14002"},{"key":"e_1_3_9_72_2","first-page":"138","article-title":"Lenvatinib vs. palliative therapy for stage IVC anaplastic thyroid cancer","volume":"12","author":"Iwasaki H","year":"2020","unstructured":"Iwasaki H, Toda S, Suganuma N, et al: Lenvatinib vs. palliative therapy for stage IVC anaplastic thyroid cancer. Mol Clin Oncol 12:138-143, 2020","journal-title":"Mol Clin Oncol"},{"key":"e_1_3_9_73_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03390-y"},{"key":"e_1_3_9_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00332-6"},{"key":"e_1_3_9_75_2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-1259"},{"key":"e_1_3_9_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30691-6"},{"key":"e_1_3_9_77_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302299"},{"key":"e_1_3_9_78_2","unstructured":"Wirth L Gao M Park YJ et al. Efficacy and safety of dabrafenib plus trametinib (D+T) in patients with radioactive iodine (RAI)\u2013refractory BRAF V600\u2013mutant differentiated thyroid cancer (DTC). Presented at the 2025 European Society for Medical Oncology (ESMO) Congress; October 17-21 2025; Berlin Germany. Abstract 2987O"},{"key":"e_1_3_9_79_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34657"},{"key":"e_1_3_9_80_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3417"},{"key":"e_1_3_9_81_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19851101)56:9<2155::AID-CNCR2820560903>3.0.CO;2-E"},{"key":"e_1_3_9_82_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-022-09707-3"},{"key":"e_1_3_9_83_2","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-23-0354"},{"key":"e_1_3_9_84_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30861"},{"key":"e_1_3_9_85_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0549"},{"key":"e_1_3_9_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1726"},{"key":"e_1_3_9_87_2","doi-asserted-by":"publisher","unstructured":"Marczyk VR Fazeli S Dadu R et al: NTRK fusion-positive thyroid carcinoma: From diagnosis to targeted therapy. JCO Precis Oncol 10.1200\/PO.24.00321","DOI":"10.1200\/PO.24.00321"},{"key":"e_1_3_9_88_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2025.0194"},{"key":"e_1_3_9_89_2","unstructured":"Madan RA: Phase II trial of pembrolizumab in recurrent or metastatic medullary thyroid cancer. 2017. https:\/\/clinicaltrials.gov\/study\/NCT03072160"},{"key":"e_1_3_9_90_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.73"},{"key":"e_1_3_9_91_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1314"},{"key":"e_1_3_9_92_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940115)73:2<432::AID-CNCR2820730231>3.0.CO;2-K"},{"key":"e_1_3_9_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.04.009"},{"key":"e_1_3_9_94_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-26-00118"},{"key":"e_1_3_9_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0027-9684(15)30409-0"},{"key":"e_1_3_9_96_2","first-page":"1","article-title":"Gender- and sexual Orientation- based inequities: Promoting inclusion, visibility, and data accuracy in oncology","volume":"42","author":"Alpert AB","year":"2022","unstructured":"Alpert AB, Scout NFN, Schabath MB, et al: Gender- and sexual Orientation- based inequities: Promoting inclusion, visibility, and data accuracy in oncology. Am Soc Clin Oncol Educ Book 42:1-17, 2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"e_1_3_9_97_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00174"},{"key":"e_1_3_9_98_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.6706"},{"key":"e_1_3_9_99_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2518"},{"key":"e_1_3_9_100_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2011.000316"},{"key":"e_1_3_9_101_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.9123"},{"key":"e_1_3_9_102_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.1183"},{"key":"e_1_3_9_103_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2012.0520"},{"key":"e_1_3_9_104_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0572"},{"key":"e_1_3_9_105_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta24020"},{"key":"e_1_3_9_106_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta23080"},{"key":"e_1_3_9_107_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00542"},{"key":"e_1_3_9_108_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01921"},{"key":"e_1_3_9_109_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00275"},{"key":"e_1_3_9_110_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03237"},{"key":"e_1_3_9_111_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00449"},{"key":"e_1_3_9_112_2","volume-title":"GRADE handbook for grading quality of evidence and strength of recommendations","author":"Sch\u00fcnemann H","year":"2013","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, et al (eds): GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group, 2013. guidelinedevelopment.org\/handbook"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-26-00235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T21:59:22Z","timestamp":1778104762000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-26-00235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,10]]},"references-count":111,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,5,10]]}},"alternative-id":["10.1200\/JCO-26-00235"],"URL":"https:\/\/doi.org\/10.1200\/jco-26-00235","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1200\/GDL.26.0401","asserted-by":"subject"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,10]]},"assertion":[{"value":"2026-01-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}